Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Initiation of phase-I clinical trial using a HuCAL-derived, fully human antibody in therapeutic area of inflammation
Subscribe to our email newsletter
MorphoSys would receive payment from Centocor Ortho Biotech in connection with the initiation of a phase-I clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.
The current program is the second HuCAL antibody derived from MorphoSys’s collaboration with Centocor Ortho Biotech to enter the clinic.
Earlier in 2007, Centocor Ortho Biotech started a phase-I study with a HuCAL antibody in oncology patients, and commenced a phase-II trial in an immunological indication using the same antibody one year later. With the new study, Centocor Ortho Biotech will be running three clinical trials for HuCAL antibodies.
Dr. Simon Moroney, CEO of MorphoSys, said: The advancement of a new HuCAL antibody into human clinical trials is an important step forward for MorphoSys.
Progress in the development of innovative biopharmaceutical agents by our partners is a key driver of our company’s growth, he added.